ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0295

Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Abstract Number: 0296

Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Abstract Number: 0297

Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry
Abstract Number: 0298

RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Abstract Number: 0299

Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
Abstract Number: 0300

Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Abstract Number: 0301

Path to Diagnosis in Familial Mediterranean Fever (FMF)
Abstract Number: 0302

TNFAIP3 Loss-of-function and Missense Mutations Demonstrate Clinically Diverse Presentations: A Multi-center Cohort Experience
Abstract Number: 0303

Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Abstract Number: 0304

Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
Abstract Number: 0305

Inflammatory T Cell Expansion in Yao Syndrome
Abstract Number: 0306

Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 0307

Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes
Abstract Number: 0308

Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Abstract Number: 0309

Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].